Assuming that CIK cells might be partly exhausted before clinical transfusion, Zhang et al. suggested implementing combined treatment on CIK cells before transfusion via antibodies targeting PD-L1, lymphocyte activation gene 3 (LAG-3), T-cell immunoglobulin mucin-3 (TIM-3), and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) in order to improve the efficiency of CIK therapy for NSCLC patients [29]. This evidence concerns the gene LAG3 and non-small cell lung carcinoma.